Free Trial
NASDAQ:TERN

Terns Pharmaceuticals Q1 2023 Earnings Report

Terns Pharmaceuticals logo
$2.40 +0.17 (+7.37%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$2.48 +0.08 (+3.33%)
As of 04/17/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Terns Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Terns Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Monday, May 15, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Terns Pharmaceuticals' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Terns Pharmaceuticals Earnings Headlines

Terns Pharmaceuticals management to meet with Oppenheimer
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Oppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)
See More Terns Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Terns Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Terns Pharmaceuticals and other key companies, straight to your email.

About Terns Pharmaceuticals

Terns Pharmaceuticals (NASDAQ:TERN), a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

View Terns Pharmaceuticals Profile

More Earnings Resources from MarketBeat